The FDA has approved Jadenu (deferasirox) tablets for the treatment of chronic iron overload according to Novartis, a global pharmaceutical company headquartered in Basel, Switzerland. Chronic iron overload is a life-threatening condition that results from blood transfusions required to treat patients with sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions. Jadenu, like its predecessor Exjade® is an iron chelator but in a new oral formulation, which can be taken in a single step simplifying administration of treatment. This drug was approved under the accelerated priority review program.

Related Links:

http://www.novartis.com/newsroom/media-releases/en/2015/1907710.shtml